Lyell Immunopharma — Third Quarter 2026 Earnings Summary

Lyell Immunopharma reported updated clinical data for its ronde-cel therapy showing a 91% overall response rate and 77% complete response rate in 44 patients with relapsed/refractory large B-cell lymphoma in the third-line or later setting. The company announced a $80.0 million private placement financing, bringing its total cash, cash equivalents, and marketable securities to approximately $194.0 million as of September 30, 2026, which is expected to fund operations into 2028. For the third quarter ended September 30, 2026, Lyell reported a net loss of $45.5 million, driven primarily by a $12.7 million increase in research and development expenses due to heightened clinical trial activity.